Abstract
The delivery of many drugs to the central nervous system (CNS) is limited due to the restrictive nature of the blood-brain barrier (BBB). The reduced paracellular diffusion and the presence of various drug efflux transporters in the brain microvessel endothelial cells forming the BBB make effective treatment of brain tumors with chemotherapeutic agents particularly problematic. While Pglycoprotein (P-gp) plays an important role in limiting BBB permeability of chemotherapeutic agents, other drug efflux transporters such as breast cancer resistance protein (BCRP) and multidrug resistance-associated proteins (MRPs) are likely to impact on chemotherapeutic levels within the brain and brain tumor. The current review examines the restrictive role that drug efflux transporters have in the delivery of chemotherapeutic agents to the brain. Consideration of different approaches taken to minimize the impact of drug efflux transporters in the BBB and improve chemotherapeutic response in treating brain tumors is also discussed.
Keywords: Blood brain barrier (BBB), brain tumor, permeability, drug efflux transport, P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), chemotherapeutic agents.
Current Pharmaceutical Design
Title:Transporter-Based Delivery of Anticancer Drugs to the Brain: Improving Brain Penetration by Minimizing Drug Efflux at the Blood-Brain Barrier
Volume: 20 Issue: 10
Author(s): Ngoc H. On and Donald W. Miller
Affiliation:
Keywords: Blood brain barrier (BBB), brain tumor, permeability, drug efflux transport, P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), chemotherapeutic agents.
Abstract: The delivery of many drugs to the central nervous system (CNS) is limited due to the restrictive nature of the blood-brain barrier (BBB). The reduced paracellular diffusion and the presence of various drug efflux transporters in the brain microvessel endothelial cells forming the BBB make effective treatment of brain tumors with chemotherapeutic agents particularly problematic. While Pglycoprotein (P-gp) plays an important role in limiting BBB permeability of chemotherapeutic agents, other drug efflux transporters such as breast cancer resistance protein (BCRP) and multidrug resistance-associated proteins (MRPs) are likely to impact on chemotherapeutic levels within the brain and brain tumor. The current review examines the restrictive role that drug efflux transporters have in the delivery of chemotherapeutic agents to the brain. Consideration of different approaches taken to minimize the impact of drug efflux transporters in the BBB and improve chemotherapeutic response in treating brain tumors is also discussed.
Export Options
About this article
Cite this article as:
On H. Ngoc and Miller W. Donald, Transporter-Based Delivery of Anticancer Drugs to the Brain: Improving Brain Penetration by Minimizing Drug Efflux at the Blood-Brain Barrier, Current Pharmaceutical Design 2014; 20 (10) . https://dx.doi.org/10.2174/13816128113199990458
DOI https://dx.doi.org/10.2174/13816128113199990458 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Role of Phospholipase D Enzyme(s) in Modulating Cell Signaling: Implications for Cancer Drug Development
Current Bioactive Compounds The Beneficial Role of Vitamin D in Human Immunodeficiency Virus Infection
Current HIV Research Studying Interactions of Drugs with Cell Membrane Nutrient Transporters: New Frontiers of Proteoliposome Nanotechnology
Current Pharmaceutical Design Emerging Treatments in Acute Lymphoblastic Leukemia
Current Cancer Drug Targets Therapeutic Gene Products Delivery by Neuron Stem Cells
Current Pharmaceutical Biotechnology Stem Cell-based Treatment Strategies for Degenerative Diseases of the Retina
Current Stem Cell Research & Therapy The Recent Electrochemical Biosensor Technologies for Monitoring of Nucleic Acid Hybridization
Current Analytical Chemistry Therapeutic Potential of Carbon Monoxide (CO) for Intestinal Inflammation
Current Medicinal Chemistry Adverse Effects and Safety of Etirinotecan Pegol, a Novel Topoisomerase Inhibitor, in Cancer Treatment: A Systematic Review
Current Cancer Therapy Reviews Random Start Ovarian Stimulation for Oocyte or Embryo Cryopreservation in Women Desiring Fertility Preservation Prior to Gonadotoxic Cancer Therapy
Current Pharmaceutical Biotechnology E-Cadherin Upregulation as a Therapeutic Goal in Cancer Treatment
Mini-Reviews in Medicinal Chemistry Development of Anti-Atherosclerosis Therapy Based on the Inflammatory and Proliferative Aspects of the Disease
Current Pharmaceutical Design Growth Factor/Peptide Receptor Imaging for the Development of Targeted Therapy in Oncology
Current Pharmaceutical Design Computer-Aided Recognition of ABC Transporters Substrates and Its Application to the Development of New Drugs for Refractory Epilepsy
Mini-Reviews in Medicinal Chemistry PepT1, ASBT-Linked Prodrug Strategy to Improve Oral Bioavailability and Tissue Targeting Distribution
Current Drug Metabolism Use of Anti-Cancer Drugs, Mitocans, to Enhance the Immune Responses against Tumors
Current Pharmaceutical Biotechnology Therapeutical Potential of CB<sub>2</sub> Receptors in Immune-Related Diseases
Current Molecular Pharmacology Role of Imaging in Testicular Cancer
Current Medical Imaging The Biological Activity of the Novel Vinca Alkaloids 4-chlorochablastine and 4-chlorochacristine
Current Cancer Drug Targets Pyridine Based Antitumour Compounds Acting at the Colchicine Site
Current Medicinal Chemistry